X0508 4 2023-12-22 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001776977 Cooke Julie 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Human Resources Officer 1 Common Stock 2023-12-22 4 M 0 14000 81.05 A 31263 D Common Stock 2023-12-22 4 S 0 14000 129.9902 D 17263 D Common Stock 2023-12-22 4 M 0 10000 61.82 A 27263 D Common Stock 2023-12-22 4 S 0 10000 126.7945 D 17263 D Non-Qualified Stock Option 81.05 2023-12-22 4 M 0 14000 81.05 D 2029-02-07 Common Stock 14000 8129 D Non-Qualified Stock Option 61.82 2023-12-22 4 M 0 10000 61.82 D 2027-10-02 Common Stock 10000 23532 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.95 to $130.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Option granted February 07, 2019 and vested monthly over four years. Option granted October 02, 2017 of which 1/4th of the shares underlying the option becomes vested and exercisable on October 02, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. /s/ Darin Lippoldt, Attorney-in-Fact 2023-12-27